In transitioning to more remote monitoring services out of necessity during COVID-19, the industry is realizing the potential to update how monitoring is routinely performed in the oversight of clinical trials. The pandemic’s impact on site availability and accessibility for patients and clinical research associates (CRAs) emphasizes the importance of evolving monitoring methodologies going beyond the industry-wide dependence on the in-person review of work performed at clinical research sites with the intent to identify mistakes and correct them. A fundamental shift in approach is needed to increase efficiency and effectiveness of clinical monitoring, continuing to ensure overall study quality and patient safety while relying more on automation and predictive analytics to continuously evaluate progress, remotely.